PMID- 1968671
OWN - NLM
STAT- MEDLINE
DCOM- 19900404
LR  - 20190907
IS  - 0278-5846 (Print)
IS  - 0278-5846 (Linking)
VI  - 14
IP  - 2
DP  - 1990
TI  - Heterocyclic antidepressant, monoamine oxidase inhibitor and neuroleptic 
      withdrawal phenomena.
PG  - 137-61
AB  - 1. The authors review the literature describing acute symptomatology produced by 
      the gradual or abrupt withdrawal of heterocyclic antidepressants, monoamine 
      oxidase inhibitors (MAOI) and neuroleptics. 2. Withdrawal of heterocyclic 
      antidepressants and antipsychotic agents causes similar symptomatology. Symptoms 
      produced by the discontinuation of these drugs include nausea, emesis, anorexia, 
      diarrhea, rhinorrhea, diaphoresis, myalgias, paresthesias, anxiety, agitation, 
      restlessness, and insomnia. 3. Psychotic relapse is often presaged by anxiety, 
      agitation, restlessness, and insomnia. Prodromal symptoms are distinguished from 
      the effects of neuroleptic withdrawal by a temporal relationship of the latter to 
      reductions in the dosage or discontinuation of antipsychotic agents. 4. 
      Withdrawal of MAOIs can result in severe anxiety, agitation, pressured speech, 
      sleeplessness or drowsiness, hallucinations, delirium, and paranoid psychosis. 5. 
      MAOI withdrawal phenomena resemble the symptoms produced by the discontinuation 
      of chronically administered psychostimulants. 6. The capacity of MAOIs to exert 
      amphetamine-like effects presynaptically and the propensity of somatic treatments 
      for depression to subsensitize presynaptic receptors regulating the release of 
      catecholamines provide a basis for the development of psychotic symptoms upon the 
      withdrawal of MAOI. Evidence for this hypothesis is reviewed.
FAU - Dilsaver, S C
AU  - Dilsaver SC
AD  - Department of Psychiatry, Ohio State University, Columbus.
LA  - eng
GR  - MH005503-3/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Antidepressive Agents, Tricyclic)
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Monoamine Oxidase Inhibitors)
SB  - IM
MH  - Antidepressive Agents, Tricyclic/*adverse effects
MH  - Antipsychotic Agents/*adverse effects
MH  - Humans
MH  - Monoamine Oxidase Inhibitors/*adverse effects
MH  - *Substance Withdrawal Syndrome/physiopathology
RF  - 108
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1016/0278-5846(90)90097-z [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(2):137-61. doi: 
      10.1016/0278-5846(90)90097-z.